The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-Cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression.
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2014
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Pharmacogenomic; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 31 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2011 Planned end date changed from 1 Jul 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.